Where healthcare capital is going in 2026, and what makes a single-specialty niche investable
SRF Capital Studio Research DeskFunding Intelligence, SRF Capital StudioAbroad, buyers paid most for supplement brands and venture funds favoured health data, while Indian investors moved into narrower clinical niches.
Summary
- By Abhijeet Mittal's count of 2026 consumer-health deals worldwide, acquirers spent most on supplement brands, and venture funds put more into blood tests, diagnostics and wearables than supplements.
- In India, investors are moving into narrower clinical niches such as orthotic products, pain management and physiotherapy, past the older bets on cancer and kidney care.
- A niche becomes investable when one clinic or one product line pays its way, and when the founder can run several sites from numbers rather than from presence.
Two readings this autumn show where healthcare money is going. One is Abhijeet Mittal's count of global consumer-health deals on LinkedIn; the other is The Economic Times' report on Indian venture bets.
Together they describe one choice. A health business can be built to be bought, for the cash its products already earn, or built to be funded, for what its data might become. Indian single-specialty founders are making that choice now, often without naming it.
Abroad, acquirers bought supplements, and health data drew more venture money
Abhijeet Mittal's mapping of 117 consumer-health deals announced from January to October 2026 is the clearest count we have seen, and its figures are global, in US dollars. He tallies about $5.05 billion of startup funding and $13.5 billion of acquisitions.
Supplements and nutrition took $10.4 billion of that acquisition total, about 77% of it. The largest deal was Procter & Gamble's agreement on 4 August to buy Thorne from L Catterton for $3.8 billion in cash. It is due to close in the fourth quarter. Kirin, Unilever and Danone also agreed deals this year for Jamieson Wellness, Grüns and Huel.
By Mittal's count, supplements also drew $1.41 billion of startup funding, but blood tests and diagnostics ($1.29 billion) and wearables ($789 million) together drew more. Neko Health, the Swedish body-scan company, raised a $700 million led by Lightspeed in July. WHOOP raised $575 million at a $10.1 billion valuation in March, according to its own release.
Consumer-health deals worldwide, announced January to October 2026, in US dollars (disclosed or reported values; six of ten categories shown, totals for all ten)
| Category | Startup funding | Acquisitions | Largest named deal |
|---|---|---|---|
| Supplements and nutrition | $1.41bn | $10.4bn | P&G buying Thorne |
| Blood tests and diagnostics | $1.29bn | Undisclosed | Neko Health's Series C |
| Wearables and rings | $789m | Undisclosed | WHOOP's Series G |
| Women's health | $541m | Undisclosed | Midi Health |
| Weight care and GLP-1 | $374m | $1.15bn | Hims & Hers buying Eucalyptus |
| Mental health | $374m | $1.14bn | UHS buying Talkspace |
| All ten categories mapped | $5.05bn | $13.5bn | 117 deals |
Health services found buyers as well. Hims & Hers completed its purchase of Eucalyptus, an Australian online health company, in June. The price is up to $1.15 billion, of which about $240 million was payable in cash at closing. Universal Health Services completed its purchase of the online therapy company Talkspace in August. The deal was valued at about $835 million, or $5.25 a share, when it was agreed in March.
Mittal expects buyers to turn next to blood tests and wearables. His bet is that Apple, Google, Meta or SpaceX will buy a wearable or blood-testing business within twelve months. That is his forecast, and we take no view on it.
An acquirer pays for cash a brand already earns: shelf space, repeat customers and a known margin. A venture fund pays for a chance at something larger whose economics are still being proved. India's healthcare deals this year show both patterns, in much narrower niches.
In India, the money is moving into narrower clinical niches
The Economic Times (ET) reported on 28 October 2026, in a piece by Ayanti Bera, that venture investors are taking their single-specialty bets past oncology and nephrology. The newer targets are orthotic products, physiotherapy and pain management. ET named three companies.
Lumov, a Bengaluru maker of orthopaedic recovery products, is in talks for a ₹32 crore round with Peak XV Partners as lead, ET reported, citing unnamed sources. Peak XV and Lumov declined to comment, so the round is unconfirmed. Lumov's last disclosed round was a seed of about ₹10 crore led by Incubate Fund Asia in December 2025, Entrackr reported.
Betterhood, which sells posture aids, back and knee supports and pain-relief products, raised ₹11.5 crore in September. Sauce VC led the and Kairon Capital took part, as Digital Health News and StartupTalky also reported.
The third is a control deal. In August, Kedaara Capital announced a $200 million investment in Tynor Orthotics, a Mohali maker of orthopaedic supports and mobility aids. ET puts the stake at about 51%. Tynor's promoters and its long-standing partner Thuasne stay involved, according to the announcement as BioSpectrum reported it.
Clinics are drawing money too. Nivaan Care, a Delhi-based chain of pain clinics staffed by pain physicians and physiotherapists, raised a $7 million led by Sorin Investments in January 2026, Entrackr reported. Bessemer Venture Partners estimated in February 2026 that India's organised single-specialty providers earned about $4.4 billion in 2025. Most of that is dialysis, fertility, eye, cancer and dental care, and Bessemer forecasts $12.3 billion by 2030.
Our hospital industry report describes single-specialty chains as businesses that earn on volume and repeatable protocols in one discipline, as HCG does in cancer care.
An orthotics brand and a pain clinic are different businesses
The Indian deals above put two kinds of company under one label. Lumov, Betterhood and Tynor sell things. Nivaan sells treatment, in a room, with a doctor. An investor who prices them the same way will misjudge one of them.
How a niche product business and a niche clinic business earn, and what an investor should test in each
| Question | A niche product, such as orthotics | A niche clinic, such as pain care |
|---|---|---|
| Where the margin is made | Unit cost against the price left after the channel's cut | Patients treated per doctor hour and per procedure room |
| The main fixed cost | Product design, tooling, stock and brand building | Rent, salaried staff, equipment and doctors' time |
| What limits growth | Shelf space, referrals and cash tied up in stock | Doctors who can deliver the protocol, and sites that fill |
| The dependence to test | One channel or one large distributor | One founding doctor whom patients come to see |
| The number to watch | Contribution per unit, channel by channel | Contribution per patient against each site's break-even |
A product business lives on its channels. Betterhood plans to widen distribution through quick commerce and modern retail. It is also building a community it puts at more than 7,000 physiotherapists, Digital Health News reported. Each route takes a different cut and sends back returns at a different rate.
A clinic lives on . Its rent, staff and equipment cost the same in a slow month. The doctor is both the product and the limit on growth. Why most Indian hospitals never scale past one location sets out what happens when patients come for the person.
The doctor is both the product and the limit on growth.
The numbers that let an investor price a niche
Karthik Beknal's Hospital Strategy series, written for hospital founders, holds most of the tools, and they scale down to a single clinic.
Start with what one patient is worth. Hospitals use ARPOB, revenue per occupied bed per day, and our ARPOB piece shows how that average misleads when stays change. A pain clinic has no beds. Its equivalent is revenue per completed course of treatment: the consultation, the procedure, the physiotherapy sessions and anything bought at the desk.
Then find each site's break-even. Divide a site's monthly fixed costs by what each course of treatment leaves after the doctor's per-case fee and consumables. Take an illustration: ₹10 lakh of monthly fixed costs and ₹5,000 left per course means 200 courses a month. The hospital break-even piece works the same sum in admissions. Every new site starts below its own line, and the months it took site two to cross are the best guide to site three.
Cost the whole episode, one service line at a time. A pain clinic usually sells consultations, procedures, physiotherapy packages and products. A procedure can look richest until the physiotherapy sessions and coordinator time it needs are counted. Our piece on department profitability argues for costing everything one patient used from admission to discharge, against what was collected. For a clinic, that episode runs from first visit to the last session. A product brand does the same by item, counting each brace's returns, channel fees and stock.
Put every site on one page. A founder with one clinic can tell how it is doing by walking in. With three clinics in three cities, nobody can. The one-page monthly review for doctor-founders sets out six blocks, from service lines and loaded margin to cash, receivables and capital projects. For a chain, give each site its own column.
Watch revenue per site as the count grows. When Hearzap bought Amplifon's Indian hearing clinics, the test we set was revenue per centre a year after integration. Roll-ups tend to break when the site count grows faster than what each site earns.
Together, these settle what every investor asks of a doctor-led clinic: whether it works without the founder in the room. If the second site reaches break-even with doctors the founder hired and trained, it does. If revenue per patient falls when the founder steps back, the business is still one person's practice.
What founders and investors should check before the next round
- Product founders should show margin per unit after each channel's cut. Quick commerce, pharmacies and physiotherapist referrals each take a different share.
- Clinic founders should prove the second site without themselves. Show patients per doctor hour, revenue per course of treatment and months to break-even, site by site.
- Fund equipment with debt and growth with equity. Sriram Chidambaram's piece on funding affordable healthcare makes the case for splitting the requirement by what the money buys.
- Investors should ask for each site's profit and loss before the blended one. A chain's average can hide one site carrying two others.
At SRF Capital Studio, we start a healthcare mandate with one site's numbers and come to the market size later. A founder who can show one clinic's break-even, and how long the second took to reach it, has a story that survives diligence.
Investors are paying attention to narrow niches. The cheque goes to the second site that fills without its founder.
Figures as of October 2026. Deal values are as announced or reported by the parties named, in the currency of the announcement.
How useful was this article?
One tap. It tells us what to write more of.
About the author
SRF Capital Studio Research Desk
Funding Intelligence, SRF Capital Studio
The next one
Get what we publish next, by email.
Working notes on raising, borrowing, protecting, growing and structuring capital in India. One email a week at most, and you can leave any time.
We use your address only to send this. See our privacy policy.
We store your address to send you these emails and nothing else. See our privacy policy.
Related content
Strategy ConsultingArticle · 5 June 2026Medical Tourism Could Be India's Most Underrated Dollar-Revenue BusinessForeign patients pay full price, often in advance and in hard currency, and they earn hospitals about 30% more per bed. India still treats medical tourism as a side business.
Strategy ConsultingArticle · 5 June 2026Why Most of India's New Hospital Beds Are Expansions, Not New BuildsIndia's hospital chains are adding tens of thousands of beds, and a large part of them are going into buildings that already exist. Here is why, what the real share is, and when a new build still makes sense.
Strategy ConsultingArticle · 5 June 2026Why Most Indian Hospitals Never Scale Past One LocationIndia has thousands of successful single hospitals and only a handful of chains. The traits that make the first hospital work are usually the ones that stop the second.
FP&A OperationsArticle · 5 June 2026The Real Economics of Running a Hospital in IndiaA hospital is a capital project that happens to treat patients. Three numbers, capex per bed, revenue per occupied bed and occupancy, decide whether it ever pays back.
Market IntelligenceMonograph · 14 October 2026The hospital industry in India: capital, care and the coming consolidationA sector report on Indian hospitals: why nobody agrees on the market size, who pays the bill, what each tier of operator earns, and how the next wave of consolidation will run.
Market IntelligenceArticle · 14 October 2026How the fabless model changed the semiconductor industryFabless chip companies design and sell chips but pay a foundry to make them. Why the split happened, how the model earns, where its risk sits, and what it means for Indian chip-design startups.
Government Grants & SchemesArticle · 14 October 2026Why do so few farmers use India's custom hiring centres?India has paid for tens of thousands of custom hiring centres, yet in Punjab only 15% of farmers who manage straw rent from them. Six reasons, from missing tractors to idle seeders.
Market IntelligenceArticle · 14 October 2026Farm mechanisation in India has left its small farms behindNearly half of India's farm work is done by machine, though little of it on the smallest farms. Where machine power sits, why a one-hectare farm cannot own a tractor, and what reaches it instead.
The services behind this article
What we do about it, for founders and finance teams. Each has its own page.
Market Intelligence
A continuous read on the sector: what is moving capital, regulation and demand, and what it means for this business.
FP&A Operations
Each month we close the books, check them against the plan, update the forecast and write the board pack, as part of your team.
Venture Capital & Private Equity
Investment readiness, fundraising strategy, diligence preparation and transaction support for founders raising institutional equity.
